[Long-term prognosis of coronary artery disease with atrial fibrillation after percutaneous coronary intervention].

Related Articles

[Long-term prognosis of coronary artery disease with atrial fibrillation after percutaneous coronary intervention].

Zhonghua Yi Xue Za Zhi. 2018 Mar 20;98(11):826-830

Authors: Wang HH, Xu JJ, Song Y, Tang XF, Jiang P, Liu R, Zhao XY, Gao Z, Zhang Y, Song L, Gao LJ, Chen J, Yang YJ, Gao RL, Qiao SB, Xu B, Yuan JQ

Abstract
Objective: To investigate the long-term prognosis of coronary artery disease with atrial fibrillation (AF) after percutaneous coronary intervention (PCI). Methods: A total of 10 724 patients with PCI were enrolled in 2013, and 2-year clinical outcomes in patients with AF (AF group) and without AF (non-AF group) were compared. Results: A total of 113 patients were with AF (1.1%), and 8 out of them were on triple antithrombotic therapy (9.5%), and AF group patients were with more complications. The 2-year follow-up results showed that the all-cause mortality in AF group was significantly higher than that in non-AF group (9.7% vs 1.1%; P<0.001). The incidence of cardiac death, stent thrombosis and stroke was also significantly higher in patients with AF. The incidence of major adverse cardiac and cerebrovascular events (MACCE) was also significantly higher in AF group compared with non-AF group (17.7% vs 8.8%; P<0.001), whereas the incidence of revascularization was significantly lower in the AF group than in the non-AF group (2.7% vs 8.7%; P=0.023). The incidence of myocardial infarction and bleeding had no significant difference between the two groups, and the adverse events between the two groups had no significant difference after propensity score (PS) either. Conclusions: The 2-year clinical follow-up of single-center, large-sample PCI patients shows poor prognosis in patients with AF compared with the non-AF patients. But there is no difference in the prognosis between the two groups after PS, however, this conclusion still needs to be confirmed by randomized controlled studies.

PMID: 29609264 [PubMed - in process]

https://ift.tt/2GwRQ0n